
12-Page Brochure
Excerpt:
Bryan Emery is active these days with his wife and sons Shon (not shown), Matthew, and Adam. For 16 years, Essential Tremor had gradually robbed Bryan of his confidence, causing him to withdraw at work, and prevented him from being active with his family. “Friends have told me it must take a lot of courage to have the surgical procedure,” he says. "I tell them it takes more courage to live with tremor every day than to have the surgery to relieve it."
|
Bounce-Back Card — Reader Interest
Excerpt:
We ask new readers if they would like to continue receiving this newsletter, and if they would like to receive additional information about Activa Therapy. You can either fill out this card and put it in the mail, or call us at 1-800-644-5111, ext. 1030.
|
Brain Autopsy Program — Letter
Excerpt:
The neuropathology report you receive will include a gross description and a microscopic description to confirm the patient’s diagnosis, to comment on other pathologies that may be present, and to describe the electrode track including microscopy of the track. The report for partial brains or blocks will be modified according to the quality and quantity of material Dr. Halliday receives.
|
Brain Autopsy Program — Instructions
Excerpt:
The electrode may have been implanted a considerable period of time before death. If so, it may be necessary to remove new bone formation to free the button.
|

Clinical Case Study
Excerpt:
The patient in this case was a 63-year-old man with a history of sudden cardiac death. During previous EP studies, ventricular tachycardia had not been inducible. The patient had dilated cardiomyopathy with a 30% left ventricular ejection fraction, NYHA Class IV. The patient had received a Jewel Plus™ Defibrillation System.
|
Company Overview Presentation
with Speaker Notes
Excerpt:
Hutchinson Technology Inc.—or “HTI”—is a world leader in the design and nano-scale manufacturing of close-tolerance computer components. HTI holds 161 granted—and approximately 80 pending—U.S. patents in chemical, mechanical, and electronic technologies.
In the late ‘80s and early ‘90s, HTI saw the opportunity to apply these leading-edge technologies to the field of biomedical measurement. After eight years of researching the medical industry, in 1996, HTI formed the BioMeasurement Division.
|
Contrast Delivery System
Press Release
Excerpt:
Minneapolis, MN, December 14, 2006 – ACIST Medical Systems announced the recent publication of a clinical study which showed that use of lower volumes of contrast media while using the ACIST Contrast Delivery System were associated with a reduced relative risk of Contrast Induced Nephropathy (CIN). The study, Automated Contrast Injection in Contemporary Practice during Cardiac Catheterization and PCI: Effects on Contrast-Induced Nephropathy, by Jason Call, et al, was published in the October 2006 issue of the Journal of Invasive Cardiology (Volume 18, Number 10, pages 469-474).
ACIST, with U.S. headquarters in Eden Prairie, MN, leads the market for variable-rate, automated contrast-delivery systems used in cardiac and vascular angiography.
|
Customer (Physician) Website
http://www.brainstimulation.net
(Use your browser's "Back" button to return to this page.)
Excerpt:
A surgically implanted Kinetra® dual-channel neurostimulator, similar to a cardiac pacemaker, delivers electrical stimulation to precisely targeted areas on each side of the brain. Bilateral stimulation of these areas controls the signals that cause the disabling bilateral motor symptoms of Parkinson's disease. Patients may also have two Soletra® or Itrel™ II neurostimulators, each controlling the electrical signals to a single lead.
|
e-Announcement of New Product
Excerpt:
Fully compatible with the existing programmer, the duel-channel Kinetra Neurostimulator improves upon the Soletra® Neurostimulator in a number of ways:
A single neurostimulator for bilateral therapy that requires fewer incisions
Additional programming option to help prevent electromagnetic fields from inadvertently shutting off the neurostimulator
Gradual decrease in battery capacity for better replacement planning
|
Employee Newsletter — New Product Announcement
Excerpt:
Pino Carbone, Movement Disorders Marketing Manager for Medtronic Neurological, Italy, and the members of his team are promoting Activa Therapy to elevate the practice of functional stereotactic neurosurgery in Italy. “We’ve had great success telling neurosurgeons about Activa Therapy,” said Carbone, “and convincing them that this surgery will increase their visibility in the neurosurgical community while alleviating tremor for their patients.”
|

Corporate Intranet Site
Excerpt:
This site is a resource center for all employees who areinvolved with or interested in market development. The focus of this resource center is to facilitate our global goal of accelerating market growth through . . . collaboration, networking, and the exchange of best practices.
|
Patient Q & A
Excerpt:
Q: Will any parts of the system show?
A: All Activa Therapy System components, with the exception of the hand-held magnet and controller, are inside the body. Depending on a person's body build, the neurostimulators may be noticeable as small bulges under the skin, but they usually are not noticeable under clothing. A doctor will try to implant the neurostimulators where they will be the most comfortable and least visible. There also may be two slight bumps at the top of the patient's head, but they usually are not visible under hair.
|
Physician e-Newsletter 1
Excerpt:
In a study published in the March 2004 issue of Neurosurgery, researchers examined the responses of patients with primary or secondary dystonia who underwent pallidotomy or received pallidal stimulation. From the abstract: "Fifteen patients with dystonia had pallidal surgery (lesions or deep brain simulation). . . . This study indicates that primary dystonia responds much better than secondary dystonia to pallidal procedures."
|
2-Page Medical Journal Ad
Excerpt:
The new Cx connector virtually guarantees implant success by accepting a supplemental electrode when necessary. Combined with Active Can™ technology’s 98% single-lead implant success, the Cx connector increases implant success to a full 100%.
|